Hospira, Inc., a Pfizer company, is voluntarily recalling lots 72680LL and 76510LL of Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL, Carpuject Single-use cartridge syringe system (NDC 0409-1782-69), to the hospital/institution level due to the potential presence of embedded and loose particulate matter on the syringe plunger.
In the event that impacted product is administered to a patient, the patient has a low likelihood of experiencing adverse events ranging from local irritation, allergic reactions, phlebitis, end-organ granuloma, tissue ischemia, pulmonary emboli, pulmonary dysfunction, pulmonary infarction, and toxicity. The risk is reduced by the possibility of detection, as the labeling contains a clear statement directing visual inspection of the product for particulate matter and discoloration prior to administration. To date, Hospira, Inc. has not received reports of any adverse events associated with this issue for these lots.
Montgomery County law enforcement agencies and emergency personnel switched to the nasal spray form of naloxone last year, which is considered to be safer. This recall will most likely affect private supplies bought by citizens as opposed to law enforcement agencies, according to Anne Stevens with Montgomery County Alcohol , Drug Addiction and Mental Health Services
Montgomery County ADAMHS spends more than $630,000 to supply police and emergency personnel with naloxone. The current recall is not expected to have an impact on local agencies since most all jurisdictions have already changed their supply to the nasal spray form.
If you require additional assistance you are asked to call 1-800-805-3093.
WHIO TV’s Malik Perkins will have more on this story on News Center 7 beginning at 5 p.m.